These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 3892155)

  • 1. Tubuloreticular inclusions in peripheral blood mononuclear cells related to systemic therapy with alpha-interferon.
    Grimley PM; Davis GL; Kang YH; Dooley JS; Strohmaier J; Hoofnagle JH
    Lab Invest; 1985 Jun; 52(6):638-49. PubMed ID: 3892155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoelectron microscopic application of monoclonal antibodies for identification of lymphocyte subsets bearing tubuloreticular inclusions or parallel tubular arrays.
    Kang YH; Yaffe L; Grimley PM
    J Exp Pathol; 1984; 1(2):157-73. PubMed ID: 6100980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
    Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
    J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic administration of human leukocyte interferon to melanoma patients. III. Increased helper:suppressor cell ratios in melanoma patients during interferon treatment.
    Karavodin LM; Golub SH
    Nat Immun Cell Growth Regul; 1983-1984; 3(4):193-202. PubMed ID: 6241293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunologic effects of interferon-alpha in man: treatment with human recombinant interferon-alpha suppresses in vitro immunoglobulin production in patients with chronic type B hepatitis.
    Peters M; Walling DM; Kelly K; Davis GL; Waggoner JG; Hoofnagle JH
    J Immunol; 1986 Nov; 137(10):3147-52. PubMed ID: 3490513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tubuloreticular reorganization of cytomembranes in cells treated with human alpha interferons--a review.
    Grimley PM; Ray S; Kostianovsky M; Rupp B; Kang YH; Feldman D
    Scanning Microsc; 1988 Dec; 2(4):2141-51. PubMed ID: 3070735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adhesion of peripheral blood mononuclear cells and CD4+ T cells from patients with psoriasis to cultured endothelial cells via the interaction between lymphocyte function-associated antigen type 1 and intercellular adhesion molecule 1.
    Watabe D; Kanno H; Yoshida A; Kurose A; Akasaka T; Sawai T
    Br J Dermatol; 2007 Aug; 157(2):259-65. PubMed ID: 17596165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetics of hepatitis B surface antigen-specific immune responses in acute and chronic hepatitis B or after HBs vaccination: stimulation of the in vitro antibody response by interferon gamma.
    Böcher WO; Herzog-Hauff S; Schlaak J; Meyer zum Büschenfeld KH; Löhr HF
    Hepatology; 1999 Jan; 29(1):238-44. PubMed ID: 9862872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parameters of interferon action: II. Immunological effects of recombinant leukocyte interferon (IFN-alpha 2) in phase I-II trials.
    Ernstoff MS; Fusi S; Kirkwood JM
    J Biol Response Mod; 1983; 2(6):540-7. PubMed ID: 6607324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppressor T cell activation by human leukocyte interferon.
    Schnaper HW; Aune TM; Pierce CW
    J Immunol; 1983 Nov; 131(5):2301-6. PubMed ID: 6226738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo and in vitro ultrastructural alterations induced by human immunodeficiency virus in human lymphoid cells.
    Yoffe B; Petrie BL; Noonan CA; Hollinger FB
    Lab Invest; 1989 Sep; 61(3):303-9. PubMed ID: 2570180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistologic and immunoelectron microscopic characterization of the mucosal lymphocytes of human small intestine by the use of monoclonal antibodies.
    Cerf-Bensussan N; Schneeberger EE; Bhan AK
    J Immunol; 1983 Jun; 130(6):2615-22. PubMed ID: 6687894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
    Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
    Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mannoprotein-induced anti-U937 cell cytotoxicity in peripheral blood mononuclear cells from uninfected or HIV-infected subjects: role of interferon-gamma and tumor necrosis factor-alpha.
    Gomez MJ; Torosantucci A; Quinti I; Testa U; Peschle C; Cassone A
    Cell Immunol; 1993 Dec; 152(2):530-43. PubMed ID: 8258154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cytokines in children with immunodeficiencies].
    Kowalczyk D
    Folia Med Cracov; 1999; 40(1-2):5-97. PubMed ID: 10909468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity.
    Edwards BS; Hawkins MJ; Borden EC
    Cancer Res; 1984 Jul; 44(7):3135-9. PubMed ID: 6586292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing effects of interleukin 2-treated peripheral blood mononuclear cells on subsequent B cell differentiation.
    Stohl W; Elliott JE; Wang H; Lin YG; Horwitz DA
    Cell Immunol; 1994 Sep; 157(2):381-92. PubMed ID: 8069923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hfgl2/fibroleukin expression in liver and peripheral blood mononuclear cells (PBMC) and its correlation with disease severity].
    Zhu F; Ning Q; Chen Y; Tao XX; Yan WM; Xi D; Yan FM; Hao LJ; Luo XP
    Zhonghua Gan Zang Bing Za Zhi; 2004 Jul; 12(7):385-8. PubMed ID: 15268797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.